Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- R&S NEWS IN BRIEF
February 5, 2007
- BUSINESS NEWS IN BRIEF
February 5, 2007
- AnGes MG Licenses Naglazyme from BioMarin
February 5, 2007
- NEW PRODUCTS
February 5, 2007
- Toyama Starts PI Trial for Anti-Flu Drug T-705
February 5, 2007
- Reexamination Period to Be Extended to Eight Years: PFSB
February 5, 2007
- Fewer than Half of All Women Aware that Pill Can Boost Fertility
February 5, 2007
- Government-private Sector Dialogue Begins
February 5, 2007
- Ajinomoto Licenses Novel Diabetes Treatment to BI
February 5, 2007
- PM Abe Calls For Strategic Support of Pharma Industry in Policy Speech
February 5, 2007
- Kansai Bio-Cluster Is No. 4 in the World: Prof. Morishita
February 5, 2007
- Course and Strategy for Japanese Economy Approved by Cabinet
February 5, 2007
- Mochida Aims to Become Specialty Pharma Focused in 4 Fields
February 5, 2007
- REGULATORY NEWS IN BRIEF
February 5, 2007
- Health Minister Yanagisawa Sees Need for Gov't to Prevent Buy-outs
February 5, 2007
- Pfizer Embarks on Major Restructuring
February 5, 2007
- COMMENTARY From Convoy System to Competition
February 5, 2007
- TOPICS 2 articles
February 5, 2007
- Council Calls For Rapid Development of Alemtuzumab, Talc
February 5, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 5, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…